|
1.
|
|
27 p, 4.1 MB |
From Single Aircraft to Communities : A Neutral Interpretation of Air Traffic Complexity Dynamics
/
Isufaj, Ralvi (Universitat Autònoma de Barcelona. Departament de Telecomunicació i Enginyeria de Sistemes) ;
Omeri, Marsel (Universitat Autònoma de Barcelona. Departament de Telecomunicació i Enginyeria de Sistemes) ;
Piera, Miquel Àngel (Universitat Autònoma de Barcelona. Departament de Telecomunicació i Enginyeria de Sistemes) ;
Saez Valls, Jaume (Universitat Autònoma de Barcelona. Departament de Telecomunicació i Enginyeria de Sistemes) ;
Verdonk Gallego, Christian Eduardo (CRIDA A.I.E)
At present, decision-making in ATM is fragmented between different stakeholders who have different objectives. This fragmentation, in unison with competing KPAs, leads to complex interdependencies between performance indicators, which results in an imbalance, with some of these indicators being penalized to the apparent benefit of others. Therefore, it is necessary to support ATM stakeholders in systematically uncovering hidden trade-offs between KPAs. Existing literature confirms this claim, but how to solve it has not been fully addressed. In this paper, we envision air traffic complexity to be the framework through which a common understanding among stakeholders is enhanced. We introduce the concept of single aircraft complexity to determine the contribution of each aircraft to the overall complexity of air traffic. Furthermore, we describe a methodology extending this concept to define complex communities, which are groups of interdependent aircraft that contribute the majority of the complexity in a certain airspace. Through use-cases based on synthetic and real historical traffic, we first show that the algorithm can serve to formalize and improve decision-making. Further, we illustrates how the provided information can be used to increase transparency of the decision makers towards different airspace users. In order to showcase the methodology, we develop a tool that visualizes different outputs of the algorithm. Lastly, we conduct sensitivity analysis in order to systematically analyse how each input affects the methodology. 2022 +520 3_ -  10.3390/aerospace9100613
Aerospace, Vol. 9, Issue 10 (October 2022) , art. 613
|
|
|
2.
|
|
25 p, 318.6 KB |
ATM and DNA-PKcs make a complementary couple in DNA double strand break repair
/
Martín Flix, Marta (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Terradas, Mariona (Universitat Autònoma de Barcelona. Departament de Biologia Animal, de Biologia Vegetal i d'Ecologia) ;
Tusell Padrós, Laura (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Genescà, Anna (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia)
The interplay between ATM and DNA-PKcs kinases during double strand breaks (DSBs) resolution is still a matter of debate. ATM and DNA-PKcs participate differently in the DNA damage response pathway (DDR), but important common aspects are indeed found: both of them are activated when faced with DSBs, they share common targets in the DDR and the absence of either kinase results in faulty DSB repair. [...]
2012 - 10.1016/j.mrrev.2011.12.006
Mutation Research - Reviews in Mutation Research, Vol. 751, Issue 1 (July-September 2012) , p. 29-35
|
|
|
3.
|
|
39 p, 4.0 MB |
Breaks invisible to the DNA damage response machinery accumulate in ATM-deficient cells
/
Martín Flix, Marta (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Terradas, Mariona (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Iliakis, George (University Duisburg-Essen Medical School) ;
Tusell Padrós, Laura (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ;
Genescà, Anna (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí")
After irradiation, ATM defective cells accumulate unrepaired double strand breaks (DSBs) for several cell divisions. At the chromosome level, unresolved DSBs appear as chromosome breaks that can be efficiently scored by using telomeric and mFISH probes. [...]
2009 - 10.1002/gcc.20679
Genes Chromosomes and Cancer, Vol. 48, Issue 9 (September 2009) , p. 745-759
|
|
|
4.
|
|
20 p, 6.8 MB |
IKKα Kinase Regulates the DNA Damage Response and Drives Chemo-resistance in Cancer
/
Colomer, Carlota (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Margalef, Pol (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Villanueva, Alberto (Institut d'Investigació Biomèdica de Bellvitge) ;
Vert, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Pecharroman, Irene (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Solé Font, Laura (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Gonzàlez-Farré, Mònica (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Alonso, Josune (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Montagut, Clara (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Martinez-Iniesta, Maria (Institut d'Investigació Biomèdica de Bellvitge) ;
Bertran, Joan (Universitat de Vic - Universitat Central de Catalunya) ;
Borràs, Eva (Centre de Regulació Genòmica) ;
Iglesias, Mar (Universitat Autònoma de Barcelona. Departament de Ciències Morfològiques) ;
Sabidó, Eduard (Centre de Regulació Genòmica) ;
Bigas Salvans, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Boulton, Simon J. (The Francis Crick Institute) ;
Espinosa, Lluís (Institut Hospital del Mar d'Investigacions Mèdiques)
Phosphorylated IKKα(p45) is a nuclear active form of the IKKα kinase that is induced by the MAP kinases BRAF and TAK1 and promotes tumor growth independent of canonical NF-κB signaling. Insights into the sources of IKKα(p45) activation and its downstream substrates in the nucleus remain to be defined. [...]
2019 - 10.1016/j.molcel.2019.05.036
Molecular Cell, Vol. 75 (august 2019) , p. 669-682.e5
|
|
|
5.
|
|
19 p, 1001.5 KB |
The ATM signaling network in development and disease
/
Stracker, Travis H. (Institut de Recerca Biomèdica de Lleida) ;
Roig, Ignasi (Ignasi) (Universitat Autònoma de Barcelona. Institut de Biotecnologia i de Biomedicina "Vicent Villar Palasí") ;
Knobel, Philip A. (Institut de Recerca Biomèdica) ;
Marjanović, Marko (Institut de Recerca Biomèdica) ;
Universitat Autònoma de Barcelona.
Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia
The DNA damage response (DDR) rapidly recognizes DNA lesions and initiates the appropriate cellular programs to maintain genome integrity. This includes the coordination of cell cycle checkpoints, transcription, translation, DNA repair, metabolism, and cell fate decisions, such as apoptosis or senescence (Jackson and Bartek, 2009). [...]
2013 - 10.3389/fgene.2013.00037
Frontiers in genetics, Vol. 4 (March 2013) , art. 37
|
|
|
6.
|
|
8 p, 473.7 KB |
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
/
Cruz, C. (Vall d'Hebron Institut d'Oncologia) ;
Castroviejo-Bermejo, Marta (Experimental Therapeutics Group) ;
Gutiérrez-Enríquez, Sara (Oncogenetics Group) ;
Llop-Guevara, A. (Experimental Therapeutics Group) ;
Ibrahim, Y. H. (Experimental Therapeutics Group) ;
Gris-Oliver, Albert. (Experimental Therapeutics Group) ;
Bonache, Sandra (Oncogenetics Group) ;
Morancho, Beatriz (Vall d'Hebron Institut d'Oncologia) ;
Bruna, Alejandra (Cancer Research UK Cambridge Institute. University of Cambridge) ;
Rueda, O. M. (Cancer Research UK Cambridge Institute. University of Cambridge) ;
Lai, Z. (AstraZeneca (USA)) ;
Polanska, U. M. (Cancer Research UK. Cambridge Institute) ;
Jones, G. N. (Cancer Research UK. Cambridge Institute) ;
Kristel, P. (The Netherlands Cancer Institute (Amsterdam, Països Baixos)) ;
de Bustos, L. (Experimental Therapeutics Group) ;
Guzmán, Marta (Experimental Therapeutics Group) ;
Rodríguez, O. (Experimental Therapeutics Group) ;
Grueso, Judit (Experimental Therapeutics Group) ;
Montalban, G. (Oncogenetics Group) ;
Caratù, Ginevra (Cancer Genomics Group) ;
Mancuso, Francesco M (Cancer Genomics Group) ;
Fasani, R. (Vall d'Hebron Institut d'Oncologia) ;
Jiménez, J. (Vall d'Hebron Institut d'Oncologia) ;
Howat, W. J. (Cancer Research UK. Cambridge Institute) ;
Dougherty, B. (AstraZeneca (USA)) ;
Vivancos, A. (Cancer Genomics Group) ;
Nuciforo, Paolo (Vall d'Hebron Institut d'Oncologia) ;
Serres-Créixams, X. (Department of Radiology) ;
Rubio Rodríguez, Isabel Teresa (Hospital Universitari Vall d'Hebron) ;
Oaknin, Ana (Vall d'Hebron Institut d'Oncologia) ;
Cadogan, E. (Cancer Research UK. Cambridge Institute) ;
Barrett, J. Carl (AstraZeneca (USA)) ;
Caldas, Carlos (NIHR Cambridge Biomedical Research Centre (Regne Unit)) ;
Baselga Torres, Josep, 1959-2021, (Memorial Sloan Kettering Cancer Center) ;
Saura, Cristina (Vall d'Hebron Institut d'Oncologia) ;
Cortés, Javier (Vall d'Hebron Institut d'Oncologia) ;
Arribas, Joaquín V. (Vicente) (Universitat Autònoma de Barcelona. Departament de Bioquímica i de Biologia Molecular) ;
Jonkers, Jos (Cancer Genomics Group) ;
Diez, Orland (Hospital Universitari Vall d'Hebron) ;
O'Connor, M. J. (Oncology Innovative Medicine and Early Development Biotech Unit. AstraZeneca (UK)) ;
Balmaña Gelpí, Judith (Vall d'Hebron Institut d'Oncologia) ;
Serra, Violeta (Vall d'Hebron Institut d'Oncologia)
BRCA1 and BRCA2 (BRCA1/2) -deficient tumors display impaired homologous recombination repair (HRR) and enhanced sensitivity to DNA damaging agents or to poly(ADP-ribose) polymerase (PARP) inhibitors (PARPi). [...]
2018 - 10.1093/annonc/mdy099
Annals of oncology, Vol. 29, Issue 5 (May 2018) , p. 1203-1210
|
|
|
7.
|
|
7 p, 4.6 MB |
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of TP53/ATM FISH deletions
/
Puiggros, Anna (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Collado, Rosa (Hospital General Universitario de Valencia) ;
Calasanz, M.J (Universidad de Navarra. Departamento de Bioquímica y Genética) ;
Ortega, Margarita (Hospital Universitari Vall d'Hebron) ;
Ruiz-Xivillé, Neus (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Rivas-Delgado, Alfredo (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Luño, Elisa (Hospital Universitario Central de Asturias) ;
González, Teresa (Fundación Pública Galega de Medicina Xenómica) ;
Navarro, Blanca (Hospital Clínic Universitari (València)) ;
García-Malo, MaDolores (Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, IMIB-Arrixaca, Murcia, Spain) ;
Valiente, Alberto (Complejo Hospitalario de Navarra) ;
Hernández, José Ángel (Hospital Universitario Infanta Leonor) ;
Ardanaz, María Teresa (Servicio de Hematología, Hospital Txagorritxu, Vitoria, Spain) ;
Piñan, María Ángeles (Hospital Universitario de Cruces (Barakaldo, País Basc)) ;
Blanco, María Laura (Institut d'Investigació Biomèdica Sant Pau) ;
Hernández-Sánchez, María (Hospital Universitario de Salamanca. Centro de Investigación del Cáncer) ;
Batlle Lopez, Ana (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ;
Salgado Sánchez, Rocío Nieves (Laboratorio de Citogenética, Servicio de Hematología, Fundación Jiménez Díaz, Madrid, Spain) ;
Salido, Marta (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Ferrer, Ana (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Abrisqueta, Pau (Hospital Universitari Vall d'Hebron) ;
Gimeno, Eva (Hospital del Mar (Barcelona, Catalunya)) ;
Abella Monreal, Eugenia (Hospital del Mar (Barcelona, Catalunya)) ;
Ferrá, Christelle (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Terol, María José (Hospital Clínic Universitari (València)) ;
Ortuño, Francisco (Servicio de Hematología y Oncología Médica, Hospital Universitario Morales Meseguer, Centro Regional de Hemodonación, IMIB-Arrixaca, Murcia, Spain) ;
Costa, Dolors (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ;
Carbonell, Félix (Hospital General Universitario de Valencia) ;
Bosch José, Francesc Xavier 1947- (Hospital Universitari Vall d'Hebron) ;
Delgado, Julio (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ;
Espinet i Solà, Blanca (Institut Hospital del Mar d'Investigacions Mèdiques) ;
Universitat Autònoma de Barcelona
Genomic complexity identified by chromosome banding analysis (CBA) predicts a worse clinical outcome in CLL patients treated either with standard or new treatments. Herein, we analyzed the clinical impact of complex karyotypes (CK) with or without high-risk FISH deletions (ATM and/or TP53, HR-FISH) in a cohort of 1045 untreated MBL/CLL patients. [...]
2017 - 10.18632/oncotarget.17350
Oncotarget, Vol. 8 (april 2017) , p. 54297-54303
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
